Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
32.62
+0.13 (0.40%)
At close: May 12, 2025, 4:00 PM
32.25
-0.37 (-1.13%)
After-hours: May 12, 2025, 7:15 PM EDT

Bright Minds Biosciences Stock Forecast

Stock Price Forecast

According to 4 professional analysts, the 12-month price target for Bright Minds Biosciences stock ranges from a low of $75 to a high of $93. The average price target of $83.25 forecasts a 155.21% increase in the stock price over the next year.

Price Target: $83.25 (+155.21%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $75 $83.25 $85 $93
Change +129.92% +155.21% +160.58% +185.10%

Analyst Ratings

The average analyst rating for Bright Minds Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Dec '24Jan '25Feb '25Mar '25Apr '25May '25
Strong Buy 011112
Buy 133333
Hold 000000
Sell 000000
Strong Sell 000000
Total 144445

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Chardan Capital
Chardan Capital
Strong Buy
Initiates
$80
Strong Buy Initiates $80 +145.25% May 7, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$85
Strong Buy Reiterates $85 +160.58% Feb 19, 2025
Piper Sandler
Piper Sandler
Buy
Initiates
$93
Buy Initiates $93 +185.10% Jan 23, 2025
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiates
n/a
Buy Initiates n/a n/a Jan 10, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$85
Strong Buy Initiates $85 +160.58% Jan 10, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.